发展血培养阳性时间作为监测耐多药革兰氏阴性菌抗生素治疗的药效学指标。

IF 3.6 2区 医学 Q1 INFECTIOUS DISEASES
Irene Zaghi, Monica Cricca, Jason A Roberts, Martina Brandolini, Claudia Colosimo, Sofia Montanari, Vittorio Sambri, Russell E Lewis
{"title":"发展血培养阳性时间作为监测耐多药革兰氏阴性菌抗生素治疗的药效学指标。","authors":"Irene Zaghi, Monica Cricca, Jason A Roberts, Martina Brandolini, Claudia Colosimo, Sofia Montanari, Vittorio Sambri, Russell E Lewis","doi":"10.1093/jac/dkaf276","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>We investigated the use of time-to-positivity (Tpos), a readily available parameter measured from automated blood culture incubators, as a surrogate marker for serum antimicrobial activity during antibiotic treatment against ESBL- and carbapenemase-producing Klebsiella pneumoniae.</p><p><strong>Methods: </strong>Banked human serum spiked with clinically representative concentrations of different antibiotics was injected into aerobic blood culture bottles containing 1 × 104 mL inoculum of K. pneumoniae isolates. The time required for the test inoculum to 'grow through' serum antibacterial activity (Tpos) was then measured over 24 h. Serum containing combinations of antibiotics were also tested using an 8 × 8 combination array to assess synergistic or antagonistic interactions.</p><p><strong>Results: </strong>Tpos increased from <10 to >24 h with increasing serum antibiotic concentrations for all drug-isolate combinations tested with the EC50 Tpos of ∼17 h for all isolates. The EC50 for ceftazidime/avibactam (4:1) ranged from 5.73 mg/L (95% CI, 5.60-5.37) for a WT strain (MIC 0.125 mg/L) to 377 mg/L (95% CI, 356.26-398.41) for a resistant KPC-3-producing isolate (MIC 16 mg/L). Variation in observed Tpos was linked to isolate MIC (R2 = 0.94). Antibiotic combinations marginally increased serum Tpos (1-3 h) for most isolates with the exception of ceftazidime/avibactam + meropenem or aztreonam against KPC-3-producing isolates (increase of 10.36-11.61 h) or ceftazidime/avibactam + aztreonam against an NDM-2 isolate (increase of 10.33 h).</p><p><strong>Conclusions: </strong>Tpos is a simple, reproducible marker of serum antibiotic activity against ESBL- and carbapenemase-producing K. pneumoniae. With further clinical validation, Tpos could be developed as a complementary surrogate marker for early detection of inadequate antimicrobial therapy in patients receiving antibiotic therapy for bloodstream infections caused by MDR Gram-negative bacteria.</p>","PeriodicalId":14969,"journal":{"name":"Journal of Antimicrobial Chemotherapy","volume":" ","pages":"2705-2713"},"PeriodicalIF":3.6000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria.\",\"authors\":\"Irene Zaghi, Monica Cricca, Jason A Roberts, Martina Brandolini, Claudia Colosimo, Sofia Montanari, Vittorio Sambri, Russell E Lewis\",\"doi\":\"10.1093/jac/dkaf276\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>We investigated the use of time-to-positivity (Tpos), a readily available parameter measured from automated blood culture incubators, as a surrogate marker for serum antimicrobial activity during antibiotic treatment against ESBL- and carbapenemase-producing Klebsiella pneumoniae.</p><p><strong>Methods: </strong>Banked human serum spiked with clinically representative concentrations of different antibiotics was injected into aerobic blood culture bottles containing 1 × 104 mL inoculum of K. pneumoniae isolates. The time required for the test inoculum to 'grow through' serum antibacterial activity (Tpos) was then measured over 24 h. Serum containing combinations of antibiotics were also tested using an 8 × 8 combination array to assess synergistic or antagonistic interactions.</p><p><strong>Results: </strong>Tpos increased from <10 to >24 h with increasing serum antibiotic concentrations for all drug-isolate combinations tested with the EC50 Tpos of ∼17 h for all isolates. The EC50 for ceftazidime/avibactam (4:1) ranged from 5.73 mg/L (95% CI, 5.60-5.37) for a WT strain (MIC 0.125 mg/L) to 377 mg/L (95% CI, 356.26-398.41) for a resistant KPC-3-producing isolate (MIC 16 mg/L). Variation in observed Tpos was linked to isolate MIC (R2 = 0.94). Antibiotic combinations marginally increased serum Tpos (1-3 h) for most isolates with the exception of ceftazidime/avibactam + meropenem or aztreonam against KPC-3-producing isolates (increase of 10.36-11.61 h) or ceftazidime/avibactam + aztreonam against an NDM-2 isolate (increase of 10.33 h).</p><p><strong>Conclusions: </strong>Tpos is a simple, reproducible marker of serum antibiotic activity against ESBL- and carbapenemase-producing K. pneumoniae. With further clinical validation, Tpos could be developed as a complementary surrogate marker for early detection of inadequate antimicrobial therapy in patients receiving antibiotic therapy for bloodstream infections caused by MDR Gram-negative bacteria.</p>\",\"PeriodicalId\":14969,\"journal\":{\"name\":\"Journal of Antimicrobial Chemotherapy\",\"volume\":\" \",\"pages\":\"2705-2713\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-10-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Antimicrobial Chemotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/jac/dkaf276\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Antimicrobial Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jac/dkaf276","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

目的:我们研究了使用自动血液培养培养箱测量的阳性时间(Tpos)作为抗生素治疗过程中产生ESBL和碳青霉烯酶的肺炎克雷伯菌的血清抗菌活性的替代标志物。方法:将具有临床代表性的不同抗生素浓度的人血清加入到含肺炎克雷伯菌分离株接种量为1 × 104 mL的有氧血培养瓶中。然后在24小时内测量试验接种物通过血清抗菌活性(Tpos)所需的时间。还使用8 × 8组合阵列测试含有抗生素组合的血清,以评估协同或拮抗相互作用。结果:Tpos从24小时开始随着血清抗生素浓度的增加而增加,所有分离物的EC50 Tpos均为~ 17小时。头孢他啶/阿维巴坦(4:1)的EC50范围从WT菌株(MIC为0.125 mg/L)的5.73 mg/L (95% CI为5.60-5.37)到产生kpc -3的耐药菌株(MIC为16 mg/L)的377 mg/L (95% CI为356.26-398.41)。观察到的Tpos变异与分离的MIC相关(R2 = 0.94)。除了头孢他啶/阿维巴坦+美罗培南或氨曲南对产生kpc -3的分离株(增加10.36-11.61小时)或头孢他啶/阿维巴坦+氨曲南对NDM-2分离株(增加10.33小时)外,大多数分离株的血清Tpos(1-3小时)轻微增加。结论:Tpos是一种简单、可重复的血清抗ESBL和产碳青霉烯酶肺炎克雷伯菌抗生素活性标志物。随着进一步的临床验证,Tpos可以作为一种补充替代标志物,用于早期检测耐多药革兰氏阴性菌引起的血流感染患者的抗菌治疗不足。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria.

Objectives: We investigated the use of time-to-positivity (Tpos), a readily available parameter measured from automated blood culture incubators, as a surrogate marker for serum antimicrobial activity during antibiotic treatment against ESBL- and carbapenemase-producing Klebsiella pneumoniae.

Methods: Banked human serum spiked with clinically representative concentrations of different antibiotics was injected into aerobic blood culture bottles containing 1 × 104 mL inoculum of K. pneumoniae isolates. The time required for the test inoculum to 'grow through' serum antibacterial activity (Tpos) was then measured over 24 h. Serum containing combinations of antibiotics were also tested using an 8 × 8 combination array to assess synergistic or antagonistic interactions.

Results: Tpos increased from <10 to >24 h with increasing serum antibiotic concentrations for all drug-isolate combinations tested with the EC50 Tpos of ∼17 h for all isolates. The EC50 for ceftazidime/avibactam (4:1) ranged from 5.73 mg/L (95% CI, 5.60-5.37) for a WT strain (MIC 0.125 mg/L) to 377 mg/L (95% CI, 356.26-398.41) for a resistant KPC-3-producing isolate (MIC 16 mg/L). Variation in observed Tpos was linked to isolate MIC (R2 = 0.94). Antibiotic combinations marginally increased serum Tpos (1-3 h) for most isolates with the exception of ceftazidime/avibactam + meropenem or aztreonam against KPC-3-producing isolates (increase of 10.36-11.61 h) or ceftazidime/avibactam + aztreonam against an NDM-2 isolate (increase of 10.33 h).

Conclusions: Tpos is a simple, reproducible marker of serum antibiotic activity against ESBL- and carbapenemase-producing K. pneumoniae. With further clinical validation, Tpos could be developed as a complementary surrogate marker for early detection of inadequate antimicrobial therapy in patients receiving antibiotic therapy for bloodstream infections caused by MDR Gram-negative bacteria.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
9.20
自引率
5.80%
发文量
423
审稿时长
2-4 weeks
期刊介绍: The Journal publishes articles that further knowledge and advance the science and application of antimicrobial chemotherapy with antibiotics and antifungal, antiviral and antiprotozoal agents. The Journal publishes primarily in human medicine, and articles in veterinary medicine likely to have an impact on global health.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信